Related Experiment Video

Updated: Jul 17, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The status of gene therapy for brain tumors

Giulia Fulci1, E Antonio Chiocca

  • 1Brain Tumor Research Center, Simches Research Building CRPZN-3800, Neurosurgery Service, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA. gfulci@partners.org

Expert Opinion on Biological Therapy
|January 26, 2007
PubMed

Insights

Gene therapy for malignant gliomas showed safety but lacked convincing therapeutic benefits in early trials. Further laboratory refinement and iterative testing are crucial for developing successful brain tumor treatments.

Area of Science:

  • Neuro-oncology
  • Gene Therapy
  • Translational Research

Background:

  • Early gene therapy trials for malignant gliomas (1990s) demonstrated safety but not significant therapeutic efficacy.
  • Initial setbacks in human trials are common for novel therapies, as seen historically with other treatments.
  • Past challenges highlight the need for iterative laboratory refinement and clinical retesting.

Purpose of the Study:

  • To summarize clinical trial results of gene therapy for malignant gliomas.
  • To discuss the impact of these trial outcomes on current preclinical research strategies.
  • To provide perspective on the development of novel brain tumor therapies.

Main Methods:

  • Review of clinical trial data for gene therapy in malignant glioma patients.
  • Analysis of historical therapeutic development trajectories.
  • Discussion of preclinical research influenced by clinical trial outcomes.

Main Results:

  • Clinical trials established the safety profile of early gene therapy for malignant gliomas.
  • Therapeutic benefits in initial human trials were not convincing, mirroring historical patterns.
  • The iterative process of laboratory study and clinical retesting is vital for therapeutic advancement.

Conclusions:

  • Initial failures in gene therapy for malignant gliomas necessitate further laboratory refinement.
  • Lessons from gene therapy trials inform current preclinical research for brain tumors.
  • Successful therapies often emerge from iterative development, combining laboratory insights with clinical validation.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors11:14

Creating Anatomically Accurate and Reproducible Intracranial Xenografts of Human Brain Tumors

Published on: September 24, 2014

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.